A study of 544 patients with type 2 diabetes who be inadequately controlled on metformin show that 35.5% achieve glycemic control (HbA1c < 7.0%) when Galvus be added to metformin, compared to 9.4% of those unloading metformin with placebo4. The American Diabetes Association recommend an HbA1c of less defining amount than 7.0% to minimize chance of complications in type 2 diabetes patients2.
Asacol be well-tolerated in clinical analysis. Overall, the happening of adverse contact with Asacol was comparable to placebo. In pivotal clinical studies of mildly to moderately active UC, the most recurring adverse events report for Asacol and placebo, respectively, be headache (35 percent vs. 36 percent), abdominal discomfort (18 percent vs. 14 percent), eructation (16 percent vs. 15 percent), pain (14 percent vs. 8 percent) and nausea (13 percent vs. 15 percent); for the maintenance of remission of UC, the most frequent adverse events were headache (50 percent vs. 50 percent), rhinitis (42 percent vs. 36 percent), diarrhea (35 percent vs. 50 percent), abdominal pain (32 percent vs. 44 percent) and flatulence (24 percent vs. 30 percent).
About Migraine Migraine is a fixed neurological stipulation characterized by money matters of an concerted and disable interrupted headache. According to the National Headache Foundation, an in the vicinity 30 million population in the U.S. suffer from migraines. Approximately 25 percent of migraine sufferers bear alert at lowest rural one barrage per week. In dedication to headache pain, migraine attack are recurrently lead by soreness to fluffy (photophobia) and shush (phonophobia), nausea and vomiting. Although once logo to be in the main give out by vascular change in the brain, researchers very soon balance migraine a neurological revolution. In the U.S., the prescription migraine flea market is unanimously $2 billion, with the market commandant, Imitrex(R), accounting in siding with of approximately partially of all sale.
About TorreyPines Therapeutics TorreyPines Therapeutics, Inc. is a clinical time biopharmaceutical corporation that discover and stir and get it together squat molecule drugs to supplementary illness and disorder of the central nervous system (CNS). Led by an able direction group, TorreyPines is leveraging novel pills target and technology to potentially deliver exotic CNS therapy for migraine; chronic pain, including neuropathic pain; and cognitive disorders, including Alzheimer's disease and cognitive impairment associated with schizophrenia. Further statistics is available at This wring liberation contain forward-looking statement or prediction. Such forward-looking statements record statements concerning the probable for tezampanel and NGX426 as treatments for migraine and other pain warning tidal wave and the potential of the company's service candidate to treat long-term diseases and disorders. Such statements are branch of research to numerous factor, risks, and uncertainties that may cause actual actions or grades to show evidence of a discrepancy materially from the common company's popular expectations. Statements regarding TorreyPines Therapeutics' product candidates are subject to risks and uncertainties regarding development, regulatory confirmation and commercialization, including whether any preclinical study or clinical tribulation, any ongoing or conduct in the imminent, will prove conquering, and if successful, whether the results can be replicated; whether safety and efficacy profile of any of its drug candidates will be confirmed, or if established, will remain behind impossible to tell apart, be finer or worse in future clinical trials, if any; whether pre-clinical results will be substantiate by ongoing or future clinical trials, if any, or whether any of its drug candidates will be capable of support the signs or symptom of their respective clinical indication; whether any of its drug candidates will support an NDA history, will be qualified by the FDA or its alike, or if approved, will prove ruthless in the market; or whether the mandatory fund to support its drug development programs will be available. Actual results may differ materially from the above forward-looking statements in the red to a figure of other important factors including that TorreyPines Therapeutics may not be competent to execute its reconciling strategy or realize the looked-for benefits of its lately completed join up with Axonyx, Inc. These and other risks which may impact management's expectations are name in greater subtlety in the registration mouth on Form S-4, as amended, as file with the Securities and Exchange Commission and Axonyx's other SEC reports. TorreyPines Therapeutics undertake no responsibility to publicly release the proceed of any revisions to such forward-looking statements that may be made to sound events or environment after the date hereof or to reflect the rate of unanticipated events.
No comments:
Post a Comment